Montefiore Multiple Sclerosis Center Research
Evolving Multiple Sclerosis Treatment for Children & Adults
The Montefiore Multiple Sclerosis Center is a patient-centered clinic focused on the diagnosis and treatment of patients with multiple sclerosis (MS) and other neuroimmunologic disorders, including neuromyelitis optica spectrum disorder (NMOSD) and autoimmune encephalitis. Our clinical research is focused on unearthing the next breakthroughs in the treatment of MS.
Areas of Concentration
Our research focuses on adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis, autoimmune encephalitis, as well as other inflammatory diseases that affect the central nervous system.
Our Research Highlights
Centrally Acting ACE Inhibition in SLE
This research study is being conducted to test the effects of a centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function. The investigators will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory and concentration) compared to benazepril, a non-centrally acting ACE inhibitor.
Exploring the Efficacy and Safety of Siponimod in Patients with Secondary Progressive Multiple Sclerosis
This study is being done in an effort to evaluate the safety and effectiveness of Siponimod (BAF312), as compared to a placebo, over various time frames in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312. The study is being carried out to obtain data on long-term safety, tolerability and efficacy.
Efficacy and Safety of Efavaleukin Alpha in Subjects with Active Systemic Lupus Erythematosus
The primary objective of this research study is to evaluate the efficacy and safety of efavaleukin alfa in subjects with active systemic lupus erythematosus.
